Suven Pharmaceuticals Ltd (NSE: SUVENPHAR): Suven Pharmaceuticals shares: Shares in the pharmaceutical sector giant Suven Pharmaceuticals rose during Saturday’s special trading session.
Suven Pharmaceuticals’ shares saw a 5 percent increase on Saturday, bringing the total return for the company to 15 percent in just two days.
On Saturday, the share price reached Rs 724.55. The share price ended the trading session at Rs 722.95, up 4.77 percent.
Merger Announced
Suven Pharmaceuticals announced the merger with Cohansa Lifesciences. The merger will create a CDMO leader in India and around the world.
Suven Pharma stated that the transaction will be completed within 12-15 months. The offer is subject to shareholder and regulatory approval.
Details Of The Company
Advent International is the private equity fund that owns both of these companies. Advent initiated the merger of Suven Pharmaceuticals with Cohansa Lifesciences.
Kotak Mahindra Capital & Citi are the advisors of the company. All shareholders of Cohance, on a swap-ratio basis, will receive 11 shares of Suven per 295 Cohance shares once the plan is implemented.
Advent will own 66.7 percent of the stake, while public shareholders will have 33.3 percent.
Trading Is Also Available On Saturday
The bullish trend continued during the second and final session on the local stock exchanges, which took place on Saturday.
Both the Sensex and Nifty closed at new records. Markets remained positive due to improved GDP figures and the capital inflow from foreign institutional investors.
On Saturday, the country’s two major stock exchanges BSE and National Stock Exchange(NSE) held a special session for trading in Equity and Equity Futures and Options to see how they would react to any disruption.
About Suven Pharmaceuticals Ltd Company
Suven Pharmaceuticals Limited is a company based in India.
The company’s main business is to develop and manufacture New Chemical Entity Intermediates (NCEIs) and Active Pharmaceutical Ingredients.
It also provides contract research and manufacturing for pharmaceutical, biotechnology, and chemical companies around the world. The company operates under the Pharmaceuticals Manufacturing and Services division.
Segments: India, the United States, and Europe.
The Company offers services and bulk drugs in India. The Company also sells services and intermediates in the United States.
The Company also sells intermediates and bulk drugs in Europe. The Company also sells services, intermediates, and bulk drugs in other countries.
Suven Pharma Inc. is the Company’s solely-owned subsidiary.
Fundamental Analysis of Suven Pharmaceuticals Ltd
| Market Cap | ₹ 18,404 Cr. |
| Current Price | ₹ 720.40 |
| 52-wk High | ₹ 768 |
| 52-wk Low | ₹ 463.30 |
| Stock P/E | 49.43 |
| Book Value | ₹ 76.0 |
| Dividend | 0.15 % |
| ROCE | 32.5 % |
| ROE | 24.5 % |
| Face Value | ₹ 1.00 |
| P/B Value | 9.49 |
| OPM | 42.7 % |
| EPS | ₹ 14.6 |
| Debt | ₹ 50.8 Cr. |
| Debt to Equity | 0.03 |
Suven Pharmaceuticals Ltd Share Price Target 2024 To 2030
| Year | 1st Target | 2nd Target |
| 2024 | ₹ 700 | ₹ 1231 |
| 2025 | ₹ 1300 | ₹ 1410 |
| 2026 | ₹ 1452 | ₹ 1480 |
| 2027 | ₹ 1500 | ₹1621 |
| 2028 | ₹ 1650 | ₹ 1789 |
| 2029 | ₹ 1800 | ₹ 1958 |
| 2030 | ₹ 2000 | ₹ 2158 |
Suven Pharmaceuticals Ltd Shareholding Pattern
| Promoters Holding | |
| Dec 2022 | 60.00% |
| Mar 2023 | 60.00% |
| June 2023 | 60.00% |
| Sept 2023 | 60.00% |
| Dec 2023 | 60.00% |
| FII Holding | |
| Dec 2022 | 8.11% |
| Mar 2023 | 9.47% |
| June 2023 | 9.50% |
| Sept 2023 | 10.01% |
| Dec 2023 | 10.14% |
| DII Holding | |
| Dec 2022 | 11.36% |
| Mar 2023 | 11.43% |
| June 2023 | 10.63% |
| Sept 2023 | 14.13% |
| Dec 2023 | 15.94% |
| Govt. Holding | |
| Dec 2022 | 0.00% |
| Mar 2023 | 0.00% |
| June 2023 | 0.01% |
| Sept 2023 | 0.01% |
| Dec 2023 | 0.01% |
| Public Holding | |
| Dec 2022 | 20.55% |
| Mar 2023 | 19.10% |
| June 2023 | 19.88% |
| Sept 2023 | 15.85% |
| Dec 2023 | 13.93% |
Suven Pharmaceuticals Ltd Share: Last 5 Years’ Financial Condition
To gain a better understanding of how the market is performing, let’s look at the outlook of this share in the previous years.
However, investors should be aware of the risks and the market conditions before making any investment decision.
Last 5 Years’ Sales:
| 2019 | ₹ 378 Cr |
| 2020 | ₹ 834 Cr |
| 2021 | ₹ 1,010 Cr |
| 2022 | ₹ 1,320 Cr |
| 2023 | ₹ 1,168 Cr |
Last 5 Years’ Net Profit:
| 2019 | ₹ 109 Cr |
| 2020 | ₹ 317 Cr |
| 2021 | ₹ 362 Cr |
| 2022 | ₹ 454 Cr |
| 2023 | ₹ 371 Cr |
Last 5 Years’ Debt-To-Equity Ratio:
| 2019 | 0.14 |
| 2020 | 0.22 |
| 2021 | 0.12 |
| 2022 | 0.06 |
| 2023 | 0 |
Last 10 Years’ Profit Growth:
| 10 Years: | — |
| 5 Years: | — |
| 3 Years: | 9% |
| Current Year: | -2% |
Last 10 years’ Return on Equity (ROE):
| 10 Years: | — |
| 5 Years: | — |
| 3 Years: | 29% |
| Last Year: | 25% |
Sales Growth Over 10 Years:
| 10 Years: | — |
| 5 Years: | — |
| 3 Years: | 17% |
| Current Year: | -13% |
Conclusion
This article is a complete guide about Suven Pharmaceuticals Ltd Share.
These information and forecasts are based on our analysis, research, company fundamentals and history, experiences, and various technical analyses.
Also, We have talked in detail about the share’s future prospects and growth potential.
Hopefully, these informations will help you in your further investment.
If you are new to our website and want to get all the latest updates related to the stock market, join us on Telegram Group.
If you have any further queries, please comment below. We will be happy to answer all your questions.
If you like this information, share the article with as many people as possible.
Disclaimer: Dear readers, we’d like to inform you that we are not authorized by SEBI (Securities and Exchange Board of India). The information on this site is only for informational and educational purposes and shouldn’t be considered financial advice or stock recommendations. Also, the share price predictions are completely for reference purposes. The price predictions will only be valid when there are positive signs on the market. Any uncertainty about the company’s future or the current state of the market will not be considered in this study. We are not responsible for any financial loss you might incur through the information on this site. We are here to provide timely updates about the stock market and financial products to help you make better investment choices. Do your own research before any investment.
